OraDel develops a technology platform for the Oral delivery of peptide/protein drugs and other problematic pharmaceuticals, which at present must be injected.
This group of active agents is characterized by their sensitivity and instability in the stomach and intestine, or by insolubility or toxicity, resulting in poor oral absorption and low bioavailability.
OraDel formulations are based on proprietary "coated proliposoms" technology, consisting of "proliposomes" powder, which is further protected by several layers of protective and enteric coatings.